Impact of the Spread of COVID-19 on Testing Demand and the Business Environment
First written in FY2020. 7 of 16 entries say "Materialised", first in FY2020. Latest entry: FY2024.
Sysmex moved to the "Worse" side of this theme in 2024, 2 years after the typical company in this theme (2022).
The whole theme swung hardest in 2022: 5 of 8 companies on the "Worse" side.
1 other company's latest entry also says "Materialised".
- FY2024MaterialisedAnnual report
「In domestic sales, reagent sales in the immunoassay field declined due to lower testing demand related to COVID-19.」
The decline in testing demand related to COVID-19 was reflected in domestic immunoassay reagent sales for the fiscal year ended March 2024. - FY2024-Q3MaterialisedAnnual report
「In domestic sales, instrument sales increased in the hematology and urinalysis fields, but reagent sales in the immunoassay field declined due to lower testing demand related to COVID-19. In addition, reagent sales in the life sciences field declined, resulting in domestic net sales of ¥43,315 million, down 1.0% year on year.」
The decline in testing demand related to COVID-19 was reflected in domestic immunoassay reagent sales for the nine months ended the third quarter. - FY2024-Q2MaterialisedAnnual report
「In domestic sales, instrument sales increased in the hematology and urinalysis fields, but reagent sales in the immunoassay field declined due to lower testing demand related to COVID-19. In addition, instrument sales in the medical robotics business declined, resulting in domestic net sales of ¥27,668 million, down 3.9% year on year.」
The decline in testing demand related to COVID-19 materialized as a decrease in domestic immunoassay reagent sales. - FY2024-Q1MaterialisedAnnual report
「In domestic sales, reagent sales in the immunoassay field declined due to lower testing demand related to COVID-19, while sales of instruments and reagents in the hematology field and reagents in the life sciences field increased.」
The decline in testing demand related to COVID-19 materialized as a decrease in domestic immunoassay reagent sales. Meanwhile, total domestic net sales increased 0.6% year on year. - FY2023-Q3MitigatedAnnual report
「In overseas sales, although the same period of the previous year was affected by the spread of COVID-19, reagent sales increased mainly in the hematology, urinalysis and blood coagulation testing fields as testing demand recovered. In addition, the yen remained weak against other currencies. As a result, the Group's overseas sales totaled ¥254,978 million, up 16.1% year on year, accounting for 85.4% of sales, up 0.5 percentage points year on year.」
Against the decline in testing demand caused by COVID-19 in the same period of the previous year, testing demand recovered and reagent sales increased, resulting in a 16.1% year-on-year increase in overseas net sales for the nine months ended the third quarter. However, the disclosure does not state that the risk posed by the pandemic itself has been eliminated. - FY2023-Q2MitigatedAnnual report
「In overseas sales, although the same period of the previous year was affected by the spread of COVID-19, reagent sales increased mainly in the hematology, urinalysis and blood coagulation testing fields as testing demand recovered. In addition, the yen remained weak against other currencies. As a result, the Group's overseas sales totaled ¥165,229 million, up 15.4% year on year, accounting for 85.1% of sales, up 0.1 percentage points year on year.」
Against the decline in testing demand caused by COVID-19 in the same period of the previous year, testing demand recovered and overseas net sales for the six months ended the second quarter increased 15.4% year on year. However, the disclosure does not state that the infectious-disease risk itself has been eliminated. - FY2023-Q1MitigatedAnnual report
「In overseas sales, although the same period of the previous year was affected by the spread of COVID-19, reagent sales increased mainly in the hematology, urinalysis and blood coagulation testing fields as testing demand recovered. In addition, the yen remained weak against other currencies. As a result, the Group's overseas sales totaled ¥73,065 million, up 8.8% year on year, accounting for 84.9% of sales, up 0.3 percentage points year on year.」
Against the decline in testing demand caused by COVID-19 in the same quarter of the previous year, testing demand recovered in the first quarter of the current fiscal year and overseas net sales increased 8.8% year on year. However, the disclosure does not state that the risk posed by the pandemic itself has been eliminated. - FY2022MaterialisedAnnual report
「The Group’s production, sales and other activities have continued without disruption through measures to prevent infection and the use of online communications. However, disruptions remain, particularly in logistics networks and the procurement of raw materials. If conditions do not improve over an extended period, the Group’s operating results and financial position could be affected.」
Although business activities themselves have continued, disruptions in logistics networks and raw-material procurement remain, extending the areas potentially affected by infectious-disease risks from declining demand to the supply side. - FY2022-Q3WorsenedAnnual report
「The COVID-19 situation remains uncertain, as the emergence of variants, including the Omicron variant, has caused social conditions in each country, including healthcare conditions, to change continually, and this uncertainty is expected to continue.」
The emergence of the Omicron variant has changed healthcare conditions and social conditions in various countries, and the disclosure states that uncertainty surrounding COVID-19 may continue. - FY2022-Q2MitigatedAnnual report
「In overseas sales, the group was affected by the spread of COVID-19 in the same period of the previous year. However, as demand for testing recovered, reagent sales increased mainly in the hematology and urinalysis fields. In addition, the yen remained weak against other currencies. As a result, the group's overseas sales were ¥143,196 million, up 29.2% year on year, and accounted for 85.0% of total sales, up 1.1 percentage points year on year.」
Against the decline in testing demand caused by COVID-19 in the same period of the previous year, testing demand recovered during the six months ended the second quarter of the current fiscal year and overseas net sales increased 29.2% year on year. However, the disclosure does not state that the risk posed by the pandemic itself has been eliminated. - FY2022-Q1MitigatedAnnual report
「In overseas sales, the group was affected by the spread of COVID-19 in the same period of the previous year. However, as demand for testing recovered, reagent sales increased mainly in the hematology and urinalysis fields. In addition, the yen remained weak against other currencies. As a result, the group's overseas sales were ¥67,136 million, up 31.3% year on year, and accounted for 84.6% of total sales, up 0.1 percentage points year on year.」
Against the decline in testing demand caused by COVID-19 in the same quarter of the previous year, testing demand recovered in the first quarter of the current fiscal year and overseas net sales increased 31.3% year on year. However, the disclosure does not state that the risk posed by the pandemic itself has been eliminated. - FY2021RestatedAnnual report
「The Company has seen a short-term decline in demand, including a reduction in the number of tests performed at medical institutions, due to restrictions on outings and other measures imposed in various countries in response to the spread of COVID-19.」
The possibility of continued declines in testing volumes at medical institutions and in demand has been reposted as a key risk. At the same time, the disclosure states that reagent demand recovered from the third quarter onward in the current fiscal year. - FY2021-Q3WorsenedAnnual report
「The Company also experienced a decline in demand, including a reduction in the number of tests performed at medical institutions, due to restrictions on outings and other measures imposed in various countries in response to the spread of COVID-19. Demand has since recovered as the pace of infections stabilized and restrictions on activities were eased, but a renewed spread of infections could have a further impact.」
The decline in testing volumes and demand caused by restrictions on outings and other measures actually occurred, and the disclosure states that a renewed spread of infections could have an additional impact even after the temporary recovery. - FY2021-Q2WorsenedAnnual report
「The Group operates globally, and has seen a short-term decline in demand, including a reduction in the number of tests performed at medical institutions, due to restrictions on outings and other measures imposed in various countries in response to the spread of COVID-19. Although the outbreak is showing signs of subsiding in some regions, including China, infections continue to increase in others. If the outbreak is prolonged, continued declines in demand and restrictions on sales activities for customers could affect the Group’s operating results and financial position.」
While some regions are showing signs of the outbreak subsiding, infections are increasing in others. The possibility of continued declines in demand and restrictions on sales activities if the outbreak is prolonged has again been identified as a key risk. - FY2021-Q1MaterialisedAnnual report
「The Company has also seen a short-term decline in demand, including a reduction in the number of tests performed at medical institutions, due to restrictions on non-essential outings in various countries. Reagent sales declined mainly in the hematology, urinalysis and immunoassay fields, largely due to the spread of COVID-19. As a result, the Group’s overseas net sales were ¥51,130 million, down 12.4% year on year.」
The decline in testing volumes at medical institutions due to the spread of COVID-19 and restrictions on outings materialized as an actual decline in demand, and overseas net sales fell 12.4% year on year. Sales in China fell 21.8%, while consolidated net sales fell 11.7%. - FY2020MaterialisedAnnual report
「The Company also recognized the possibility of a short-term decline in demand, including a reduction in the number of tests performed at hospitals, due to restrictions on hospital access for conditions other than COVID-19 and restrictions on non-essential testing. The impact on net sales was recognized as follows: first quarter of the fiscal year ending March 2021: testing demand was expected to decline in each region, down 10% to 15% year on year; second quarter of the fiscal year ending March 2021: signs of recovery were seen in China, Europe and the United States, narrowing the decline to a slight year-on-year decrease.」
The decline in testing demand and its impact on net sales were quantified for the first time in specific terms following the spread of COVID-19 and restrictions on access to medical institutions and non-essential testing.